CD274 and alveolar soft part sarcoma: A Phase II clinical trial (n = 28, evidence level 3) conducted by Tan et al. (59) investigated the efficacy of anlotinib combined with the PD-L1 inhibitor TQB2450 in patients with advanced ASPS.